Table 4.
The combination index (CI)* values for the mango pulp (M) and eprosartan drug (E) co-administration on major tested parameters
| Parameters | CI* | Effect |
|---|---|---|
| GSH | 2.9 ± 0.1 | Anti-synergistic |
| GSSG | 1.7 ± 0.0 | Anti-synergistic |
| GSH/GSSG | 5.1 ± 0.3 | Anti-synergistic |
| GPx | 2.6 ± 0.2 | Anti-synergistic |
| SOD | 1.5 ± 0.1 | Anti-synergistic |
| GST | 1.3 ± 0.0 | Anti-synergistic |
| GSR | 2.9 ± 0.2 | Anti-synergistic |
| MDA | 2.5 ± 0.2 | Anti-synergistic |
| PDGF-BB | 1.9 ± 0.1 | Anti-synergistic |
| TNF-α | 2.4 ± 0.4 | Anti-synergistic |
| TGF-β1 | 2.3 ± 0.2 | Anti-synergistic |
GSH (glutathione), GSSG (reduced glutathione), GPx (glutathione peroxidase), SOD (superoxide dismutase), GST (glutathione-S-transferase), GSR (glutathione reductase), MDA (malonedialdehyde), TNF-α (tumor necrosis factor-α), and PDGF-BB (platelet-derived growth factor-BB), and TGF-β1 (transforming growth factor-beta1 and the data are being presented as the mean ± SD
* CI values determine the type of impact between E and M. the effect can be evaluated as synergism (CI < 1), anti-synergism (CI > 1), or additive (CI = 1) (Zhou et al. 2007; Habashy et al. 2018; Shaban et al. 2020, 2021a, 2022)